Related Experiment Videos
Treatment of experimental infections of mice with bacteriophages
1Department of Infection, Medical School, Edgbaston, Birmingham.
Abstract:
Bacteriophages for Acinetobacter baumanii, Pseudomonas aeruginosa and Staphylococcus aureus were tested in experimental infections of mice to investigate their potential for the treatment of infections of man. As few as 10(2) particles of an acinetobacter phage protected mice against 5 LD50 (1 x 10(8)) of a virulent strain of A. baumanii, and phage was demonstrated to have multiplied in the mice. A pseudomonas phage protected mice against 5 LD50 of a virulent strain of P. aeruginosa, with a PD50 of 1.2 x 10(7) particles. A staphylococcal phage failed to protect mice infected with a strain of S. aureus. These studies support the view that bacteriophages could be useful in the treatment of human infections caused by antibiotic-resistant strains of bacteria.
Insights
Bacteriophages show promise for treating bacterial infections. Acinetobacter and Pseudomonas phages protected mice, but Staphylococcus phages did not, suggesting potential for antibiotic-resistant infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Bacteriophage Therapy
Background:
- Antibiotic resistance is a growing global health threat.
- Bacteriophages (phages) are viruses that infect bacteria and are being explored as an alternative to antibiotics.
- Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus are significant human pathogens, often exhibiting multidrug resistance.
Purpose of the Study:
- To evaluate the therapeutic potential of bacteriophages against experimental infections caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus in a mouse model.
- To determine the efficacy of specific phages in protecting mice against lethal doses of these bacteria.
Main Methods:
- Experimental infections were established in mice using virulent strains of A. baumannii, P. aeruginosa, and S. aureus.
- Mice were treated with specific bacteriophages to assess protection against lethal bacterial challenge.
- The protective dose 50 (PD50) and lethal dose 50 (LD50) were determined for the phages and bacteria, respectively.
- Bacteriophage replication within the host was also investigated.
Main Results:
- A single acinetobacter phage demonstrated significant protection, with as few as 10(2) particles preventing mortality against 5 LD50 of A. baumannii. Phage multiplication was confirmed in vivo.
- A pseudomonas phage provided protection against P. aeruginosa, with a PD50 of 1.2 x 10(7) particles.
- A staphylococcal phage failed to protect mice infected with S. aureus, indicating strain-specific efficacy or limitations.
Conclusions:
- Bacteriophage therapy shows potential for treating infections caused by Acinetobacter baumannii and Pseudomonas aeruginosa.
- The efficacy of bacteriophage therapy is specific to the bacterial species and phage used.
- Further research is warranted to explore the clinical application of bacteriophages against antibiotic-resistant bacterial infections.